These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 26061272)
21. Epidermal growth factor receptor blockers for the treatment of ovarian cancer. Morrison J; Thoma C; Goodall RJ; Lyons TJ; Gaitskell K; Wiggans AJ; Bryant A Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007927. PubMed ID: 30321910 [TBL] [Abstract][Full Text] [Related]
22. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis. Tian W; Ding W; Kim S; Xu X; Pan M; Chen S Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis. Ren Z; Sun J; Sun X; Hou H; Li K; Ge Q Oncotarget; 2017 Jul; 8(29):48253-48262. PubMed ID: 28477027 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y Asian Pac J Cancer Prev; 2012; 13(10):5177-82. PubMed ID: 23244131 [TBL] [Abstract][Full Text] [Related]
26. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. Chen LT; Oh DY; Ryu MH; Yeh KH; Yeo W; Carlesi R; Cheng R; Kim J; Orlando M; Kang YK Cancer Res Treat; 2017 Oct; 49(4):851-868. PubMed ID: 28052652 [TBL] [Abstract][Full Text] [Related]
27. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Li BT; Barnes TA; Chan DL; Naidoo J; Lee A; Khasraw M; Marx GM; Kris MG; Clarke SJ; Drilon A; Rudin CM; Pavlakis N Lung Cancer; 2016 Dec; 102():21-27. PubMed ID: 27987583 [TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials. Zhao N; Wu ZP; Yang J; Feng WN; Yang SL; Luo Y; Ye J; Wang F; Zhang XW; Xiao Y; Wu LL; Gu WQ World J Surg Oncol; 2023 Feb; 21(1):45. PubMed ID: 36782320 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis. Yu J; Zhang Y; Leung LH; Liu L; Yang F; Yao X J Hematol Oncol; 2016 Oct; 9(1):111. PubMed ID: 27756337 [TBL] [Abstract][Full Text] [Related]
30. The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials. Wang BC; Zhang WX; Kuang BH; Lin GH PLoS One; 2022; 17(10):e0275919. PubMed ID: 36215289 [TBL] [Abstract][Full Text] [Related]
31. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials. Shan F; Miao R; Xue K; Li Z; Li Z; Bu Z; Wu A; Zhang L; Wu X; Zong X; Wang X; Li S; Ji X; Jia Z; Li Z; Ji J Cancer Lett; 2016 Oct; 380(2):598-607. PubMed ID: 26724681 [TBL] [Abstract][Full Text] [Related]
32. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials. Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560 [TBL] [Abstract][Full Text] [Related]
33. Targeted therapy for gastric cancer: Current status and future directions (Review). Yuan DD; Zhu ZX; Zhang X; Liu J Oncol Rep; 2016 Mar; 35(3):1245-54. PubMed ID: 26718131 [TBL] [Abstract][Full Text] [Related]
34. Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Zhang TT; Wang RM; Yang Z; Chen GB Clin Transl Oncol; 2016 Jun; 18(6):576-81. PubMed ID: 26527033 [TBL] [Abstract][Full Text] [Related]
35. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Wagner AD; Thomssen C; Haerting J; Unverzagt S Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials. Tian Y; Lin J; Tian Y; Zhang G; Zeng X; Zheng R; Zhang W; Yuan Y Int J Cancer; 2018 Jun; 142(11):2198-2206. PubMed ID: 29143328 [TBL] [Abstract][Full Text] [Related]
37. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs. Sheng Z; Zhang Y Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830 [TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, advanced gastric cancer: systematic review and network meta-analysis. Cai T; Liang L; Zhao X; Lin C; Li D; Zheng J Crit Rev Oncol Hematol; 2024 Jan; 193():104216. PubMed ID: 38029945 [TBL] [Abstract][Full Text] [Related]
39. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. Qin K; Hou H; Liang Y; Zhang X BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384 [TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]